PD98059isaMEKinhibitorwithIC₅₀of5μM,alsosuppressesTCDDbindingtothearylhydrocarbonreceptor(AHR)withIC₅₀of4μM.

IC50:5μM(MEK)^[1]

ConcentrationsofPD98059of≤20μMarenotcytotoxictoculturedMCF10A,MCF10A-Neo,andMCF10A-NeoTcells.However,PD98059isweaklycytostatictoallthreelinesatconcentrationsof≥10μM.TreatmentofMCF10A-NeoandMCF10A-NeoTcultureswithconcentrationsofPD98059upto20μMfor2-22hrdoesnotalterthetotalERKcontent.However,treatmentwithPD98059doesresultinconcentration-dependentreductionsintheduallyphosphorylatedformsofERK1andERK2.Within2hrofa10-μMtreatment,phosphorylatedERKcontentsarereduced~74%and~86%inMCF10A-NeoandMCF10A-NeoTcultures,respectively(IC₅₀=1μM).Within22hroftreatment,phosphorylatedERKformsarealmostcompletelyeliminatedinbothcelllines^[1].PD98059(PD098059)preventstheactivationofMAPKK1byRaforMEKkinaseinvitroatconcentrations(IC₅₀=2-7μM).PD98059inhibitsboththeactivationandphosphorylationofMAPKK1invitrobyeitherc-RaforMEKkinasewithIC₅₀valuesof4±2μM.IncubationofSwiss3T3cellswithPD98059(50μM)suppressedby80-90%theactivationofMAPKKinducedbyeachagoNIST,buttheactivationofc-Rafisenhanced2-3-fold^[2].

ThetreatmentofmicewithPD98059significantlyreducesthelevelofp-ERK1/2.Moreover,asignificantincreaseinthephospho-p38expressionisobservedinZymosan-treatedmiceat18hafterZymosanadministrationcomparedtothesham-operatedmice.ThetreatmentwithPD98059significantlyreducesthep38expression^[3].RepeatedtreatmentwithPD98059attenuatesmechanicalallodyniameasuredbythevonFreytestthree(18.0g±0.8,n=10)andseven(20.21g±0.67,n=26)daysafterCCIincomparisontothevehicle-treatedCCI-exposedrats(15.1g±1.3,n=7and14.21g±0.44,n=28,respectively).RepeatedinjectionofPD98059diminishesthermalhyperalgesia,asisevaluatedbythecoldplatetest,three(17.5s±2.1,n=10)andseven(25.54s±1.03,n=26)daysfollowingCCIcomparedtovehicle-treatedCCI-exposedrats(11.5s±1.8,n=7and11.4s±0.88,n=28,respectively)^[4].

• [1].ReinersJJJr,etal.PD98059isanequipotentantagonistofthearylhydrocarbonreceptorandinhibitorofmitogen-activatedproteinkinasekinase.MolPharmacol.1998Mar;53(3):438-45.

  [2].AlessiDR,etal.PD098059isaspecificinhibitoroftheactivationofmitogen-activatedproteinkinasekinaseinvitroandinvivo.JBiolChem,1995,270(46),27489-27494.

  [3].DiPaolaR,etal.PD98059,aspecificMAPkinaseinhibitor,attenuatesmultipleorgandysfunctionsyndrome/failure(MODS)inducedbyzymosaninmice.PharmacolRes.2010Feb;61(2):175-87.

  [4].RojewskaE,etal.PD98059InfluencesImmuneFactorsandEnhancesOpioidAnalgesiainModelofNeuropathy.PLoSOne.2015Oct1;10(10):e0138583.

Kinasereactionsareperformedin50μLreactionvolumesandcontain50mMTris,pH7.4,10mMMgCl₂,2mMEGTA,10μMATP(containing1μCiof3000Ci/mmol[γ-³²P]ATP),7.6μgofGST-MEK1,7.2μgofGST-ERK1,and20μgofMBP.PD98059andotherflavonoidsareaddedtothereactionsmixturesimmediatelyaftertheadditionofGST-MEK1butbeforetheadditionofGST-ERK1andATP.ControlreactionscontainERK1andMBPbutnoMEK.Reactionmixturesareincubatedat30°Cfor15minbeforebeingstoppedbytheadditionofLaemmli’sSDSsamplebuffer.ProteinsareseparatedonSDS-15%polyacrylamidegels.Aftervacuumdryingofthegel,rADIoactivityisdetectedbyautoradiographyonX-rayfilmorphosphoimagingusingaBioRadGS-525MolecularImager^[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

PD98059isdissolvedinDMSOandstored,andthendilutedwithappropriatemedia(DMSO<0.1%) before="">^[1].

TheMCF10A,MCF10A-Neo,andMCF10A-NeoTcelllinesareused.SubconfluentculturesaretreatedwithPD98059(0-100μM).ViABIlityofcellsaftertreatmentisassessedbyabilitytoexcludetrypanblue.CulturesearmarkedforRNAisolationarewashedtwicewithphosphate-bufferedsaline(2.7mMKCl,1.5mMKH₂PO₄,137mMNaCl,8mMNa₂HPO₄,pH7.2)atharvestingandstoredat-80°C^[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

PD98059ispreparedinnon-pyrogenicsaline(0.9%NaCl)(Mice)^[3].
PD98059isdissolvedin75%DMSO(Rat)^[4].

Mice^[3]
MaleCDmice(20-22g)arerandomlyallocatedintothefollowinggroups:1.Zymosan+DMSOgroup.Micearetreatedintraperitoneally(i.p.)withZymosan(500mg/kg,sUSPendedinsalinesolution)andwiththevehicleforPD98059(10%DMSO,v/v)i.p.1and6hafterZymosanadministration(N=10).2.PD98059group.IdenticaltotheZymosan+DMSOgroupbutareadministeredPD98059(10mg/kg,i.p.bolus)at1and6hafterZymosan(N=10)insteadofDMSO.3.Sham+DMSOgroup.IdenticaltotheZymosan+DMSOgroupbutareadministeredsalinesolutioninsteadofZymosan(N=10).4.Sham+PD98059group.IdenticaltoSham+DMSOgroup,exceptfortheadministrationofPD98059(10mg/kgi.p.bolus)1and6haftersalineadministration(N=10).
Rat^[4]
Therats(maleWistar,300-350g)areused.ThePD98059(2.5μg/5μL,i.t.)issingleorrepeatedpreemptivelyadministered16hand1hbeforeCCIandthenoncedailyfor7days.TheVehicle-treatedCCI-exposedratsreceive75%DMSOaccordingtothesameschedule.Thereisnosignificantdifferenceinpainbehaviorbetweenno-treatedandV(DMSO)-treatedCCI-exposedrats.ThismethodofPD98059orvehicleadministrationisusedthroughoutthestudyandisreferredtointhetextas“repeatedadministration”.Atday7^thafterCCI30minafterPD98059administrationtactileallodyniaismeasuredusingvonFreytestandthermalhyperalgesiaisconductedusingcoldplatetest.Additionally,atday7^thafterCCIthevehicle-treatedandPD98059-treatedratsreceiveasinglei.t.vehicle,Morphine(2.5μg/5μL)orBuprenorphine(2.5μg/5μL)injection30minafterPD98059,andthen30minlaterthevonFreyand/orcoldplatetestsarerepeated.Sincethedoseofmorphine2.5μg/5μLinnaiveratsproducesmaximalanalgesiceffectintail-flicktest.LowerdoseofMorphineareusedforco-administrationexperiments,sothatobservingthepossIBLeenhancementofopioideffectiveness.Thevehicle-treatedandPD98059-treatednaiverats(uninjuredrats)receiveasinglei.t.vehicle,Morphine(0.5μg/5μL)orBuprenorphine(2.5μg/5μL)injection30minafterPD98059,andthen30minlaterthetailflicktestisperformed.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

• [1].ReinersJJJr,etal.PD98059isanequipotentantagonistofthearylhydrocarbonreceptorandinhibitorofmitogen-activatedproteinkinasekinase.MolPharmacol.1998Mar;53(3):438-45.

  [2].AlessiDR,etal.PD098059isaspecificinhibitoroftheactivationofmitogen-activatedproteinkinasekinaseinvitroandinvivo.JBiolChem,1995,270(46),27489-27494.

  [3].DiPaolaR,etal.PD98059,aspecificMAPkinaseinhibitor,attenuatesmultipleorgandysfunctionsyndrome/failure(MODS)inducedbyzymosaninmice.PharmacolRes.2010Feb;61(2):175-87.

  [4].RojewskaE,etal.PD98059InfluencesImmuneFactorsandEnhancesOpioidAnalgesiainModelofNeuropathy.PLoSOne.2015Oct1;10(10):e0138583.

267.28

C₁₆H₁₃NO₃

167869-21-8

RoomtemperatureincontinentalUS;mayvaryelsewhere

DMSO:16mg/mL;H₂O:<0.01="">

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:99.45%

SelectBatch:HY-12028-12294HY-12028-12764HY-12028-09811

DataSheet(125KB)SDS(276KB)

COA(94KB)HNMR(141KB)LCMS(191KB)

HandlingInstructions(1252KB)

• [1].ReinersJJJr,etal.PD98059isanequipotentantagonistofthearylhydrocarbonreceptorandinhibitorofmitogen-activatedproteinkinasekinase.MolPharmacol.1998Mar;53(3):438-45.

  [2].AlessiDR,etal.PD098059isaspecificinhibitoroftheactivationofmitogen-activatedproteinkinasekinaseinvitroandinvivo.JBiolChem,1995,270(46),27489-27494.

  [3].DiPaolaR,etal.PD98059,aspecificMAPkinaseinhibitor,attenuatesmultipleorgandysfunctionsyndrome/failure(MODS)inducedbyzymosaninmice.PharmacolRes.2010Feb;61(2):175-87.

  [4].RojewskaE,etal.PD98059InfluencesImmuneFactorsandEnhancesOpioidAnalgesiainModelofNeuropathy.PLoSOne.2015Oct1;10(10):e0138583.

品牌介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH，5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50～89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者，应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射，并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似，均可达81%～100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用，可加快代谢，故快代谢型者需增加剂量，慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶，熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride)：C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应，可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品

公司介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-

品牌分类

黄酮类化合物 抑制性抗体 苯丙素类 酸和醛 醌类 肽 其他 酚类 萜类和糖苷类

类固醇 生物碱 糖类和糖苷类 染料试剂 生化分析试剂

显示分类

联络我们

服务热线：4000-520-616

（限工作日9:00-18:00）

QQ ：1570468124

手机：18915418616

官网：http://www.medchemexpress.com/

快速导航：

公司介绍

产品中心

新闻动态

在线咨询

联系我们

公司介绍

产品中心

新闻动态

在线咨询

联系我们

总部地址：

江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)

工作时间：周一至周五9:00~18:00

技术支持：

Email：info@ebiomall.com

短信：18915418616

服务热线：

4000-520-616（全国）

☏  0512-67156496（苏州）

版权信息：

©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国

网站备案：

苏ICP备17049038号-1

苏公网安备 32059002001627号

友情链接：

联系QQ:764052152

medix清关 medkoo官网 megazyme采购 microspheres代购 midlandsci报价 minerva正品 molecular molinnov moltox mpbio relassay产品 ​​polysciences药物筛选 electronmicroscopysc viskase 22mm MD34 apiclab华东代理 美国Lumigen imgenexindia代理 蚂蚁淘 广东兰瑟贸易有限公司

免责声明：

本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。

扫描二维码关注官方微信

获取最新促销及产品信息